Pfizer (PFE) FDA Approves XALKORI for Lung Cancer

Thank you for joining us. I am your host Yohemy Auerbach at CRWE Newswire Stocks to watch. Pfizer Incorporated - symbol PFE - reported that the U.S. Food and Drug Administration has approved its XALKORI. the first-ever therapy targeting anaplastic lymphoma kinase, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test. lung cancer is responsible for more deaths in both men and women each year worldwide than any other type of cancer. Pfizer’s XALKORI is an advance in the treatment of this devastating illness, providing a new therapeutic option for a subset of patients with the disease. Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Yohemy Auerbach